GM102
Phase 2- Indications
- Cancer
Company intelligence / Profile preview
GamaMabs Pharma
Toulouse, Occitanie, Franceeurobiomed.org ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Phase 2
01
Overview
GamaMabs developed first-in-class monoclonal antibodies targeting AMHR2 for oncology indications. Its lead asset murlentamab was well tolerated in Phase 1/2 trials but showed only modest single-agent efficacy and was discontinued in early 2021. The company’s AMHR2 franchise—including drug product and manufacturing cell lines—was acquired by Exelixis in May 2021. Preclinical data supported the potential of AMHR2 as a novel target for solid tumors
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyAntibody-drug conjugate (ADC)Biologic (for low-fucose EMABling® antibodies)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MedImmune/AstraZeneca [licensing agreement for ADC technology/PBD toxin linker technology]LFB Biotechnologies [licensed EMABling® platform technology]
Beyond the preview
Go deeper on GamaMabs Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GamaMabs Pharma.